Obviously, the risk of OHSS is directly related to the ovarian response [26, 27], but may be mitigated in a long GnRH agonist protocol by excluding potential high responders (e.g. those with AMH > 35 pmol/L) who benefit more from individualized follitropin delta treatment in a GnRH antagonist protocol [28]. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.